Kulik W, van Weissenbruch M M, Menelik N, Cranendonk A, Kneepkens C M, Lafeber H N
Department of Clinical Chemistry, University Hospital Vrije Universiteit, Amsterdam, The Netherlands.
J Chromatogr B Biomed Sci Appl. 2001 Jan 5;750(1):147-53. doi: 10.1016/s0378-4347(00)00441-2.
The [13C]octanoic acid breath test was used for the measurement of differences in gastric emptying in preterm infants for the evaluation of pharmacological therapy. In order to perform a good intra-individual comparison of the gastric emptying in preterm infants under non-standardisable test conditions, we adjusted t1/2 for variations in non-recovered label (=label retention) and introduced an "effective half 13CO2 breath excretion time" t1/2eff = t1/2/m expressed as min per percentage of the cumulative dose recovered. In a pilot study, we investigated the action of the gastrointestinal prokinetic drug cisapride on gastric emptying in seven premature infants, of whom four suffered from gastric stasis and three had constipation. The postnatal age and weight at the start of treatment ranged from 15 to 64 days and from 815 to 1635 g, respectively. All infants received the standard formula for premature infants (Nenatal, Nutricia). Cisapride was administered orally 0.2 mg/kg, four times daily. The changes in gastrointestinal motility were studied using the total bowel transit time of carmine red. After 7 days of treatment in all children, the gastric emptying coefficient and the half 13CO2 breath excretion time adjusted for label retention were improved (n=7, the gastric emptying coefficient range before treatment was 1.69-3.34 (mean 2.59 +/- 0.80) and after treatment it was 2.79-3.76 (mean 3.28 +/- 0.30); the half 13CO2 breath excretion time adjusted for label retention range before treatment was 3.0-14.7 min/% dose (mean 7.0 +/- 5.0) and after treatment 2.6-4.0 min/% dose (mean 3.1 +/- 0.6). The total bowel transit time was only slightly improved in two patients (n=7, mean total bowel transit time before: 23.7 h compared to mean total bowel transit time after 7 days of treatment: 35.5 h). Side effects during cisapride treatment were not seen. We conclude that in premature infants cisapride is effective in shortening gastric emptying time and reducing gastric stasis; the therapeutic role in constipation has to be further investigated.
[13C]辛酸呼气试验用于测量早产儿胃排空的差异,以评估药物治疗效果。为了在不可标准化的测试条件下对早产儿的胃排空进行良好的个体内比较,我们针对未回收标记物的变化(即标记物保留)调整了t1/2,并引入了“有效13CO2呼气排泄半衰期”t1/2eff = t1/2/m,以每分钟回收累积剂量的百分比表示。在一项初步研究中,我们调查了胃肠道促动力药物西沙必利对7名早产儿胃排空的作用,其中4名患有胃潴留,3名患有便秘。治疗开始时的出生后年龄和体重分别为15至64天和815至1635克。所有婴儿均接受早产儿标准配方奶粉(Nenatal,纽迪希亚)。西沙必利口服给药,剂量为0.2 mg/kg,每日4次。使用胭脂红的全肠转运时间研究胃肠动力的变化。所有儿童治疗7天后,调整标记物保留后的胃排空系数和13CO2呼气排泄半衰期均得到改善(n = 7,治疗前胃排空系数范围为1.69 - 3.34(平均2.59 +/- 0.80),治疗后为2.79 - 3.76(平均3.28 +/- 0.30);调整标记物保留后的13CO2呼气排泄半衰期范围治疗前为3.0 - 14.7分钟/%剂量(平均7.0 +/- 5.0),治疗后为2.6 - 4.0分钟/%剂量(平均3.1 +/- 0.6)。仅2例患者的全肠转运时间略有改善(n = 7,治疗前平均全肠转运时间:23.7小时,治疗7天后平均全肠转运时间:35.5小时)。西沙必利治疗期间未见副作用。我们得出结论,在早产儿中,西沙必利可有效缩短胃排空时间并减少胃潴留;其在便秘治疗中的作用有待进一步研究。